ClinicalTrials.gg
Active, not recruitingNCT04711148Updated Apr 21, 2023

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

A Phase 2 interventional study of placebo and orelabrutinib in Relapsing Remitting Multiple Sclerosis, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Active, not recruiting at 42 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Ukraine — none open to participants now, 6 under way, 4 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Ukraine.

Planned enrollment
37th of 41
160 · median 500
Started
2021
the only one that year
Phase 2
16 of 41
none open now
Registered
38th of 41
by date

Among the 41 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Ukraine, this one is the 37th largest by planned enrollment, is the only one that started in 2021, is one of 16 in phase 2, and was the 38th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 41 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Ukraine is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Ukraine as a file.
02

Study summary

This is a randomized, double-Blind, placebo-controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis.

Read the detailed description

The study contains 2 parts: Core Part and an Open-label Extension (OLE) Part.

The Core Part is a randomized, double-blind, placebo-controlled, phase 2 study. Patients with RRMS will be randomly assigned to 1 of 4 treatment groups. placebo, orelabrutinib (low dose), orelabrutinib (medium dose) and orelabrutinib (high dose) at a 1:1:1:1 ratio.

The OLE part is an open-label, single treatment arm study to enroll patients who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data.All patients will receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study.

03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are 18 to 55 years of age at the time of signing the .
  2. Are diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS).
  3. Are neurologically stable for ≥ 30 days prior to both Screening and Baseline.
  4. One or more documented relapses within the 2 years before Screening
  5. Have an EDSS score of 0 to 5.5 at Screening and Baseline (Day 1)
  6. Women of must use effective method of
  7. Signed and dated informed consent
  8. Patient currently participating in the Core Part who has completed the end of treatment visit and will be benefit from continued treatment per investigator's assessment. (OLE Part only)

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with progressive MS.
  2. Disease duration > 10 years in participants with an EDSS ≤ 2.0 at Screening and Baseline (Day 1).
  3. Immunologic disorder other than MS.
  4. History or current diagnosis of other neurological disorders that may mimic MS.
  5. History or current diagnosis of progressive multifocal leukoencephalopathy (PML).
  6. History of myocardial infarction or cerebrovascular event within 6 months prior to Screening,
  7. A history of attempted suicide within 6 months prior to Screening or a positive response to items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening.
  8. An episode of major depression within the last 6 months prior to Screening (clinically stable minor depression is not exclusionary).
  9. History of cancer, except adequately treated basal cell or squamous cell carcinoma of the skin
  10. Breastfeeding/lactating or pregnant women
  11. Participants are excluded from participation in the study if taken prohibited medications/treatments.
  12. Participation in any drug study within 6 months or 5 half-lives of the investigational drug, whichever is longest, prior to Screening.
  13. Permanent discontinuation from the Core Part due to AE/ SAE or abnormal abnormalities or conditions leading to permanent study drug discontinuation. (OLE Part only)
  14. Patient who has new abnormality appeared in the Core Part. (OLE Part only)
  15. Any significant change in the subject's medical history that would preclude administration of the study drug. (OLE Part only)
  16. laboratory abnormalities from the most recently available test in the Core Part that would preclude administration of the study drug. (OLE Part only)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    The Core Part:Participants receive placebo The OLE Part:Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study.

    Other: placebo · Drug: orelabrutinib

  • Experimental
    orelabrutinib(low dose)

    The Core Part:Participants receive low dose orelabrutinib The OLE Part:Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study.

    Drug: orelabrutinib

  • Experimental
    orelabrutinib(medium dose)

    The Core Part :Participants receive medium dose orelabrutinib The OLE Part:Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study.

    Drug: orelabrutinib

  • Experimental
    orelabrutinib (high dose)

    The Core Part:Participants receive high dose orelabrutinib The OLE Part:Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study.

    Drug: orelabrutinib

Interventions

  • Otherplacebo

    placebo

  • Orelabrutinib is a white, round, uncoated tablet

06

What researchers measure

Primary outcomes

  1. The cumulative number of new GdE T1 MRI brain lesions

    To evaluate the efficacy of orelabrutinib on the cumulative number of new gadolinium-enhancing (GdE) T1 magnetic resonance (MRI) brain lesions versus placebo over 12 weeks of treatment.

    Time frame: up to 120 weeks

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability ]

    To evaluate the safety and tolerability of orelabrutinib compared to placebo in the Core Part

    Time frame: up to 120 weeks

  2. ARR[efficacy]

    Annualized relapse rate in the OLE Part

    Time frame: up to 120 weeks

Other outcomes

  1. Peak concentration (Cmax)

    Dose Escalation Peak concentration (Cmax)

    Time frame: up to 120 weeks

07

Study locations

42 sites
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Consultants in Neurology LTD
    Northbrook, Illinois 60062, United States
  • Neurology Associates, P.C.
    Lincoln, Nebraska 68510, United States
  • Premier Neurology, P.C.
    Greer, South Carolina 29650, United States
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing 100070, China
  • The First Affiliated Hospital of Chongqing Medical University
    Yuzhong, Chongqing 400016, China
  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430060, China
  • Xiangya Hospital, Central South University
    Changsha, Hunan 410008, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Shengjing Hospital of China Medical University
    Shengyang, Liaoning 110004, China
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai 200040, China
  • The 1st Affiliated Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • The Second Affiliated Hospital of Air Force Military Medical University
    Xi'an, Shanxi 710038, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • NZOZ Wielospecjalistyczna Poradnia Lekarska "Synapsis"
    Katowice, 40-123, Poland
  • Prywatna Praktyka Lekarska
    Katowice, 40-571, Poland
  • Resmedica NZOZ Kielce
    Kielce, 25-726, Poland
  • MCD Medical
    Krakow, 31-637, Poland
  • Neuromed
    Lublin, 20-954, Poland
  • Nzoz "Neuro-Kard"
    Poznan, 61-853, Poland
  • Wielospecjalistyczne Centrum Medyczne Ibismed
    Zabrze, 41-807, Poland
  • CE I.I.Mechnykov Dnipropetrovsk RC Hosp of Dnipropetrovsk RC Dept of Neurology
    Dnipro, 49005, Ukraine
  • Medical Center of Dnipro State Medical University, Dnipro State Medical University
    Dnipro, 49027, Ukraine
  • SI USSRI of Medical and Social Problems of Disabilities of MOHU
    Dnipro, 49027, Ukraine
  • CNE Regional Clinical Hospital of Ivano-Frankivsk Regional Council
    Ivano-Frankivsk, 76008, Ukraine
  • Institute of Neurology, Psychiatry and Narcology of NAMSU
    Kharkiv, 61068, Ukraine
  • SI Institute of Neurology, Psychiatry and Narcology of NAMSU
    Kharkiv, 61068, Ukraine
  • CIH Kharkiv City General Practice
    Kharkiv, 61172, Ukraine
  • Medical Center of Limited Liability Company Medbud-Clinic
    Kyiv, 3110, Ukraine
  • CNE of Lviv Reg Council Lviv Reg Clin Hospital Dept of Neurology D.Halytskyi Lviv NMU
    Lviv, 79010, Ukraine
  • CNE City Clinical Hospital #5 of Lviv
    Lviv, 79013, Ukraine
  • CNE Odesa Regional Clinical Hospital of Odesa Regional Council
    Odesa, 65025, Ukraine
  • Medical Center of Limited Liability Company Health Clinic, Medical Clinical Research Center
    Vinnytsia, 21009, Ukraine
  • Medical Center of Limited Liability Company Medical Center Saliutem
    Vinnytsia, 21050, Ukraine
  • Municipal Non-profit Enterprise "City Hospital No.6" of Zaporizhzya City Council
    Zaporizhzhia, 69035, Ukraine
  • CNE Zaporizhzhia RCH of ZRC Dept of Neurology #1
    Zaporizhzhia, 69600, Ukraine
  • CNE Zaporizhzhia Regional Clinical Hospital of ZRC
    Zaporizhzhia, 69600, Ukraine
  • Medical Center of Limited Liability Company INET-09
    Zaporizhzhya, 69035, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Feb 2026, 59 months after the start.

Of 25 phase 2 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2021
First posted
Jan 15, 2021
StartActual
Mar 1, 2021
Primary completionEst.
Feb 25, 2026
CompletionEst.
Mar 1, 2026
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04711148
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Mar 1, 2021
Primary completion
Feb 25, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Apr 21, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion